Agreement between prostate cancer patients and their clinicians about utilities and attribute importance

Health Expectations

Volumn 7, Issue 2, 2004, Pages 115-125

  Elstein, Arthur S ^a,g   Chapman, Gretchen B ^b   Chmiel, Joan S ^c   Knight, Sara J ^d,e   Chan, Cheeling ^c   Nadler, Robert B ^c   Kuzel, Timothy M ^c   Siston, Amy K ^c   Bennett, Charles L ^c,f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JESSE BROWN VA MEDICAL CENTER   (United States)

^g VA Chicago Healthcare System ^*  (United States)

Author keywords

Preferences; Substituted judgement; Utility assessment; Values

Indexed keywords

ARTICLE; CANCER PATIENT; CORRELATION ANALYSIS; DOCTOR PATIENT RELATION; EVALUATION; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NORMAL HUMAN; PATIENT ATTITUDE; PATIENT GUIDANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER;

DECISION MAKING; HEALTH STATUS; HUMANS; MALE; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 2442647628     PISSN: 13696513     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1369-7625.2004.00267.x     Document Type: Article

References (49)

1. O'Connor AM, Rostom A, Fiset V et al. Decision aids for patients facing health treatment or screening decisions: systematic review. British Medical Journal, 1999; 312: 731-734.
2. Kassirer JP. Incorporating patients' preferences into medical decisions. New England Journal of Medicine, 1994; 330: 1895-1896.
3. Chan EC, Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? American Journal of Medicine, 1998; 105: 354-355.
4. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. Journal of Urology, 2001; 166: 947-952.
5. Weinstein MC, Fineberg HV, Elstein AS et al. Clinical Decision Analysis. Philadelphia: Saunders, 1980.
6. Hunink M, Glasziou P, Siegel J et al. Decision Making in Health and Medicine: Integrating Evidence and Values. New York: Cambridge University Press, 2001.
7. Rouse DJ, Owen J. Decision analysis. Clinical Obstetrics and Gynecology, 1998; 41: 282-295.
8. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. New England Journal of Medicine, 2002; 347: 781-789.
9. Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. New England Journal of Medicine, 2002; 347: 790-796.
10. Chodak GW. Comparing treatments for localized prostate cancer: persisting uncertainty. JAMA, 1998; 280: 1008-1010.
11. Fleming C, Wasson JH, Albertsen PC et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA, 1993; 269: 2650-2658.
12. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. Journal of Urology, 1994; 152: 1894-1899.
13. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. Journal of General Internal Medicine, 1997; 12: 299-305.
14. Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM. Prostate cancer screening: a decision analysis. Journal of Family Practice, 1995; 41: 33-41.
15. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA, 1994; 272: 773-780.
16. Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Medical Decision Making, 1998; 18: 376-380.
17. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Cummings BJ. Whose utilities for decision analysis? Medical Decision Making, 1990; 10: 58-67.
18. Stiggelbout AM. Assessing patients' preferences. In: Chapman GB, Sonnenberg FA (eds) Decision Making in Health Care: Theory, Psychology, and Applications. New York: Cambridge University Press, 2000: 289-312.
19. Goldstein MK, Tsevat J. Applying utility assessment at the bedside. In: Chapman GB, Sonnenberg FA (eds) Decision Making in Health Care: Theory, Psychology, and Applications. New York: Cambridge University Press, 2000: 313-333.
20. Chapman GB, Elstein AS, Sharifi R, Kuzel T, Andrews A, Bennett CL. Prostate cancer patients' utility for health states: how it looks depends on where you stand. Medical Decision Making, 1998; 18: 278-286.
21. Clarke AE, Goldstein MK, Michelson D, Garber AM, Lenert LA. The effect of assessment method and respondent population on utilities elicited for Gaucher's disease. Quality of Life Research, 1997; 6: 169-184.
22. Jimison HB, Sher PP. Advances in presenting health information to patients. In: Chapman GB, Sonnenberg FA (eds) Decision Making in Health Care: Theory, Psychology, and Applications. New York: Cambridge University Press, 2000: 334-361.
23. Coppola KM, Ditto PH, Danks JH, Smucker WD. Accuracy of primary care and hospital-based physicians' predictions of elderly outpatients' treatment preferences with and without advance directives. Archives of Internal Medicine, 2001; 161: 431-440.
24. Ditto PH, Danks JH, Smucker WD et al. Advance directives as acts of communication: a randomized controlled trial. Archives of Internal Medicine, 2001; 161: 421-430.
25. Fagerlin A, Ditto PH, Danks JH, Houts RM, Smucker WD. Projection in surrogate decisions about life-sustaining medical treatments. Health Psychology, 2001; 20: 166-175.
26. Sulmasy DP, Haller K, Terry PB. More talk, less paper: predicting the accuracy of substituted judgments. American Journal of Medicine, 1994; 96: 432-438.
27. Sulmasy DP, Terry PB, Weisman CS et al. The accuracy of substituted judgments in patients with terminal diagnoses. Annals of Internal Medicine, 1998; 128: 621-629.
28. Seckler AB, Meier DE, Mulvihill M, Paris BE. Substituted judgment: how accurate are proxy predictions? Annals of Internal Medicine, 1991; 115: 92-98.
29. Suhl J, Simons P, Reedy T, Garrick T. Myth of substituted judgment: surrogate decision making regarding life support. Archives of Internal Medicine, 1998; 105: 90-96.
30. Fischer GS, Tulsky JA, Rose MR, Siminoff LA, Arnold RM. Patient knowledge and physician predictions of treatment preferences after discussion of advance directives. Journal of General Internal Medicine, 1998; 13: 447-454.
31. da Silva FC, Reis E, Costa T, Denis L. Quality of life in patients with prostatic cancer: a feasibility study. Cancer, 1993; 71(Suppl. 3): 1138-1142.
32. Cassileth BR, Soloway MS, Vogelzang NJ et al. Quality of life and psychosocial status in stage D prostate cancer patients. Quality of Life Research, 1992; 1: 323-329.
33. Fossa SD, Aaronson NK, Newling D et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. European Journal of Cancer, 1990; 26: 1133-1136.
34. Litwin MS, Hays RD, Fink A et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA, 1995; 273: 129-135.
35. Herr HW, Kornblith AB, Ofman UA. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer, 1993; 71(Suppl.): 1143-1150.
36. Pedersen KV, Carlsson P, Rahmquist M et al. Quality of life after radical retropubic prostatectomy for carcinoma of the prostate. European Urology, 1993; 4: 7-11.
37. Bennett CL, Matchar D, Crawford D. Cost-effectiveness models of flutamide: are they helpful to policy-makers? Cancer, 1996; 9: 1854-1861.
38. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Services Research, 1972; 7: 118-133.
39. Froberg DG, Kane RL. Methodology for measuring health-state preferences - II: Scaling methods. Journal of Clinical Epidemiology, 1989; 42: 459-471.
40. Chapman GB, Elstein AS. Utility assessment: methods and research. In: Bennett CL, Stinson TJ (eds) Cancer Policy: Research and Methods. Boston: Kluwer, 1998: 13-23.
41. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. Journal of Chronic Diseases, 1978; 31: 697-704.
42. Suarez-Almazor ME, Conner-Spady B, Kendall CJ, Russell AS, Skeith K. Lack of congruence in the ratings of patients' health status by patients and their physicians. Medical Decision Making, 2001; 21: 113-121.
43. Schneiderman LJ, Kaplan RM, Pearlman RA, Teetzel, H. Do physicians' own preferences for life-sustaining treatment influence their perceptions of patients' preferences? Journal of Clinical Ethics, 1993; 4: 28-33.
44. Schneiderman LJ, Kaplan RM, Rosenberg E, Teetzel H. Do physicians' own preferences for life-sustaining treatment influence their perceptions of patients' preferences? A second look. Cambridge Quarterly of Healthcare Ethics, 1997; 6: 131-137.
45. Au E, Loprinzi CL, Dhodapkar M et al. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity. Journal of Clinical Oncology, 1994; 12: 2751-2755.
46. Clipp EC, George LK. Patients with cancer and their spouse caregivers: perceptions of the illness experience. Cancer, 1992; 69: 1074-1079.
47. Knight SJ, Chmiel JS, Sharp LK et al. Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity. Urology, 2001; 57: 275-280.
48. Sneeuw KC, Aaronson NK, Osoba D et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Medical Care, 1997; 35: 490-506.
49. Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH. Value of caregiver ratings in evaluating the quality of life of patients with cancer. Journal of Clinical Oncology, 1997; 15: 1206-1217.